Evidence map›Paper›PMID 27330760›Full record

ArticleMolecular and clinical oncology2016

Disseminated intravascular coagulation observed following treatment with gemtuzumab ozogamicin for relapsed/refractory acute promyelocytic leukemia.

Yoshiko Azuma, Aya Nakaya, Masaaki Hotta, Shinya Fujita, Yukie Tsubokura, Hideaki Yoshimura, Atsushi Satake, Kazuyoshi Ishii, Tomoki Ito, Shosaku Nomura

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular and clinical oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Yoshiko AzumaThe First Department of Internal Medicine, Kansai Medical University, Hirakata, Osaka 573-1010, Japan.
Aya NakayaThe First Department of Internal Medicine, Kansai Medical University, Hirakata, Osaka 573-1010, Japan.
Masaaki HottaThe First Department of Internal Medicine, Kansai Medical University, Hirakata, Osaka 573-1010, Japan.
Shinya FujitaThe First Department of Internal Medicine, Kansai Medical University, Hirakata, Osaka 573-1010, Japan.
Yukie TsubokuraThe First Department of Internal Medicine, Kansai Medical University, Hirakata, Osaka 573-1010, Japan.
Hideaki YoshimuraThe First Department of Internal Medicine, Kansai Medical University, Hirakata, Osaka 573-1010, Japan.
Atsushi SatakeThe First Department of Internal Medicine, Kansai Medical University, Hirakata, Osaka 573-1010, Japan.
Kazuyoshi IshiiThe First Department of Internal Medicine, Kansai Medical University, Hirakata, Osaka 573-1010, Japan.
Tomoki ItoThe First Department of Internal Medicine, Kansai Medical University, Hirakata, Osaka 573-1010, Japan.
Shosaku NomuraThe First Department of Internal Medicine, Kansai Medical University, Hirakata, Osaka 573-1010, Japan.
Kansai Medical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gemtuzumab ozogamicin (GO) is a recombinant humanized immunoglobulin G4 anti-cluster of differentiation (CD)33 monoclonal antibody conjugated to N-acetyl-γ calicheamicin dimethylhydrazide, a naturally potent antibiotic. It has been introduced for the treatment of acute promyelocytic leukemia (APL), since large quantities of CD33 are commonly expressed on the surface of APL cells. The present study reported two cases with prominent disseminated intravascular coagulation (DIC), which was transiently observed following treatment with GO with relapsed/refractory APL. Very limited information exists regarding DIC occurring following GO, and its mechanism remains to be elucidated. In the present study, recombinant human soluble thrombomodulin was used for DIC treatment, and the patients recovered promptly. Since DIC is the most serious adverse event associated with GO treatment, elucidation of its mechanism and establishment of a treatment strategy are warranted.

Indexed as

acute promyelocytic leukemiadisseminated intravascular coagulationgemtuzumab ozogamicin

Identifiers

PMID27330760
PMCPMC4906953
OpenAlexW2338430098

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.